• Hemispherx Biopharma Inc., of Philadelphia, said Ampligen (rintatolimod), an experimental immunotherapeutic, was administered intranasally in conjunction with FluMist (influenza vaccine live, intranasal) to healthy volunteers in a study at the University of Alabama at Birmingham.